News | June 19, 2013

Healthy test subjects with amyloid plaque were also found to have hypometabolism indicating a potential Alzheimer’s precursor

June 19, 2013 — Alzheimer’s disease has been linked in many studies to amyloid plaque buildup in the brain, but new research is finding a common thread between amyloid burden and lower energy levels, or metabolism, of neurons in certain areas of the brain associated with Alzheimer’s disease — even for people with no sign of cognitive decline. This is a new development in the understanding of Alzheimer’s pathology, say neuroscientists presenting the research at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting.

“This study shows that there is an association between hypometabolism and amyloid in the brains of normal people,” said Val J. Lowe, M.D., a professor of radiology at Mayo Clinic Cancer Center based in Rochester, Minn. “Previous studies indicate that hypometabolism of this same pattern is present in patients who have abnormalities of the gene apolipoprotein E, or APOE. The hypothesis is that people who have these genetic abnormalities tend to have hypometabolism and are on the trajectory toward developing Alzheimer’s disease. Hypometabolism does appear to be an early harbinger of the disease before dementia sets in.”

The research is a part of a longitudinal multi-phase study called the Mayo Clinic Study of Aging, which includes 2,500 patients with 4,000 projected for the next phase. For this imaging study, 617 cognitively normal subjects underwent two separate positron emission tomography (PET) procedures, a molecular imaging technique that visualizes physiological processes in the body. Each subject was imaged with an amyloid-binding radionuclide imaging agent, C-11 Pittsburgh compound B (PiB), produced on-site at the Mayo Clinic. An hour later, all patients were imaged again using the same scanner and a different radionuclide agent, F-18 fluorodeoxyglucose (FDG), which shows up on scans as hot-and-cold spots according to metabolic brain cell activity.

Results were then analyzed via quantitative analysis and reviewed. Researchers found significant hypometabolism in brain regions classically associated with Alzheimer’s disease, including the angular gyrus and posterior cingulate. Even the PiB PET scans that were deemed barely positive for amyloid were partnered with FDG PET scans that showed corresponding hypometabolism.

For more information: www.snmmi.org


Related Content

News | Lung Imaging

Sept. 8, 2026 – Brainomix and Endeavor BioMedicines recently presented positive results from the Brainomix AI-driven ...

Time September 09, 2026
arrow
News | Ultrasound Imaging

Sept. 2, 2026 – Sonex Health and The Institute of Advanced Ultrasound Guided Procedures have announced publication of ...

Time September 04, 2026
arrow
News | Women's Health

Sept. 1, 2026 — On Sept. 24, 2026 at 1 p.m. EDT, Siemens Healthineers will present a webinar on "Advancing Women's ...

Time September 03, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiopharmaceuticals and Tracers

Aug. 30, 2026 — Bayer has announced the presentation of first detailed results from the Phase III REVEAL study, an ...

Time September 02, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026— A new study from the Harvey L. Neiman Health Policy Institute found that the odds of imaging following an ...

Time September 01, 2026
arrow
News | RSNA

Aug. 18, 2026 —The board of trustees of the Radiological Society of North America's (RSNA) Research & Education (R&E) ...

Time August 24, 2026
arrow
News | PET Imaging

Aug. 14, 2026 — Lantheus Holdings recently announced U.S. Food and Drug Administration (FDA) approval of Tauklarify ...

Time August 20, 2026
arrow
News | PET Imaging

July 14, 2026 — New research is shedding new light on the biological basis of schizophrenia by directly measuring ...

Time July 15, 2026
arrow
News | Radiation Oncology

July 8, 2026 — GE HealthCare and Mayo Clinic have announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy ...

Time July 09, 2026
arrow
Subscribe Now